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Barriers to early detection of cognitive impairment in the elderly despite the availability 
of simple cognitive screening tools and the pharmacist’s role in early detection and 
referral 
Abstract 
Aim: The aim of this review is to identify suitable cognitive screening tool that can be used 
by the pharmacist during home medication review in addition to calculating the medications 
total anticholinergic burden.  
Data sources: A search of literature was conducted using PubMed, Embase, and Medline 
and Google Scholar databases to identify relevant studies using the following keywords: 
‗cognitive impairment‘, ‗cognitive impairment AND diagnosis‘, ‗cognitive scales‘, 
‗dementia‘, ‗delirium‘, ‗pharmacist role‘, ‗mini-mental state examination (MMSE)‘, ‗the 
Rowland dementia assessment scale (RUDAS)‘, ‗the Alzheimer‘s Disease Assessment Scale- 
Cognition (ADAS-Cog)‘  and ‗barriers and problems‘. Only informational websites, clinical 
trials and review articles were included. 
Results: The mini-mental state examination (MMSE), the Rowland Dementia Assessment 
Scale (RUDAS), the Alzheimer‘s disease Assessment Scale- Cognition (ADAS-Cog), 
Psychogeriatric Assessment Scale (PAS) and Kimberley Indigenous Cognitive Assessment 
(KICA-Cog) require specialists training. The anxiety and depression checklist (K10) and 
worried about your memory (WAYM) can be self-administered without prior training. 
Anticholinergic burden (ACB) scoring system can also be used to determine the total 
medications anticholinergic burden. 
Conclusion: The anxiety and depression checklist (K10) and worried about your memory 
(WAYM) can be used by the pharmacist during medication reviews to early detect and refer 
the elderly for further medical care supported by the calculated score for the patient total 
medications anticholinergic burden. 
Appendix XIII Paper in submission to Journal of Pharmacy Practice and Research, Result awaited
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Introduction 
Cognitive function is a concept of multidimensional domains which are associated with the 
performance of normal healthy brain, including psychomotor ability, concentration and attention, 
information processing speed, executive function, visuospatial skill, language, memory and learning.
1
 
Cognitive impairment is the deterioration in the function of either one or a number of these domains.
2
  
This may be in a form of a single specific impairment or a group of related impairments.
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Furthermore, cognitive impairment is inferred from an individual‘s behaviour rather than observed 
directly. Mild cognitive impairment (MCI), isolated memory impairment or incipient dementia is a 
brain function disorder which involves  the evolution and onset of cognitive deficits beyond those 
anticipated based on the  individuals‘ age and education,  but these deficits are not significant enough 
to  disturb the individuals‘ activities of daily living.3 Also, MCI has been described as a transitional 
state between standard cognitive function and Alzheimer‘s disease (AD).4  
There has been a dramatic increase in the use of cognitive screening tests to provide detection tools 
and objective measures of cognitive functioning over the last 10 years. A substantial number of 
screening tests exist including the mini-mental state examination (MMSE), the Rowland Dementia 
Assessment Scale (RUDAS), the Alzheimer‘s disease Assessment Scale- Cognition (ADAS-Cog), 
Psychogeriatric Assessment Scale (PAS) and Kimberley Indigenous Cognitive Assessment (KICA-
Cog), Anxiety and depression checklist (K10) and worried about your memory (WAYM) (table 1). 
Due to the effect of some medications on cognition, the pharmacist is in a good position to use the 
Anticholinergic Cognitive Burden scale (ACB) to guide their advice to other health professionals who 
then can provide the required clinical interventions. ACB is used as a research tool to examine the use 
of anticholinergic medications in population with high risk such as demented patients. Based on 
medications anticholinergic properties, each medication is given a score of 1, 2 or 3. Fox et al. (2011) 
allocated a score of either two or three is given to medications which definitely possess 
anticholinergic effects and a score of one is given to medications with potential anticholinergic 
effects.
5
 For each medication with definite anticholinergic effects Fox et al. (2011) concluded that a 
46% increase in cognitive impairment risk may result over six years and  that the rise in the total score 
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of ACB by one point was linked with the increased risk of death by 26% and a reduction in MMSE 
score by 0.33 points over 2 years.
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Aim  
This review is a part of a parent study which aims to investigate the role of pharmacist, in 
early detection of medication that may compromise the elderly cognition, during home 
medication review, and early referral to treating doctor for further action whenever possible. 
The aim of this review is to identify suitable cognitive screening tool that can be used by the 
pharmacist during medication review in addition to calculating the medications total 
anticholinergic burden. 
Method   
In order to check the validity of current tools available to tests cognition and the possibility of 
pharmacists administering these tests, a search of literature was conducted using PubMed, 
Embase, Medline and Google Scholar databases to identify relevant studies using the 
following keywords: ‗cognitive impairment‘, ‗cognitive impairment AND diagnosis‘, 
‗cognitive scales‘, ‗dementia‘, ‗delirium‘, ‗pharmacist role‘, ‗mini-mental state examination 
(MMSE)‘, ‗the Rowland dementia assessment scale (RUDAS)‘, ‗the Alzheimer‘s Disease 
Assessment Scale- Cognition (ADAS-Cog)‘ and ‗barriers and problems‘.  
Number of tools was identified as potential tools that can be used in primary care setting 
(table 1). Only informational websites, clinical trials and review articles were included. Those 
were directly related to the review and the parent study concept is listed in table 2 and 3. 
Literature Review 
The diagnosis of different cognitive impairments is challenging. Despite the presence of different 
diagnostic tools to distinguish between different cognitive impairments causes and levels, getting a 
correct diagnosis still considered as a significant challenge.
7
 For instance, delirium may be overlooked 
when mild, considered as part of normal aging, or incorrectly diagnosed as a psychiatric illness e.g. 
depression or dementia. Many studies showed that physician failed to recognise 32-67% of delirious 
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patients.
7, 8
 Additionally, other studies demonstrated that cognitive function is rarely formally assessed 
unless it is reported as an issue by the patient
9
 and there is frequently minimal knowledge about the 
course of any cognitive impairment or the baseline cognitive status of patients.
10
 Although delirium 
has the potential to be the sole manifestation of a serious illnesses such as myocardial infarction (MI) 
or sepsis, it is not usually considered as a significant clinical syndrome due to their acute nature and 
its multiple and varied aetiologies among the elderly which may present as atypical to the known 
disease presentation.
10
 Health professionals tend to pay attention when delirious patient present with 
inappropriate behaviours, hallucinations and agitation; whereas delirium  associated with lethargy and 
decreased activity is commonly missed.
10
 One study found that 37% of 74 patients considered 
depressed by house staff consultees were actually re-diagnosed by the consulting psychiatrist and 
found to suffer from delirium.
11
 Furthermore, another study conducted by Tiamson, et al. (1993) 
showed that about 27% of 677 depressed patients were actually suffering of an organic mental 
disorder after they re-diagnosed by consulting psychiatrist.
12
 Another study demonstrated the low 
sensitivity of the diagnosis of delirium by emergency department doctors although the prevalence of 
delirium among elderly patients in this department is relatively high.
13
 Johnson et al. (1992) noted that 
delirium was explicitly recognised in only 5% of the studied elderly general hospital admissions.
14
 
Also, the study showed that 25% of the missed cases were diagnosed as a functional psychiatric 
disorder while 25% of the cases were diagnosed as dementia and 50% of the cases were documented 
as no diagnosis.
14
 Patients with mild dementia can also suffer from delirium due to other underlying 
causes, which may early worsen their quality of life than if it is managed.
15
 Additionally, it has been 
shown that hypoactive delirium, which accounts for 25% of cases, is most likely to be missed as it is 
mistakenly diagnosed as depression and/or its symptoms don‘t disturb other people.16 One study, 
which was conducted in two geriatric hospitals, showed that the diagnosis of different cognitive 
impairments among hospitalized older patients was insufficient.
17
 The cognitive impairment was 
recorded in medical notes in 79.5% of the cases and the cognitive testing was conducted on only 
47.7% of patients with diagnosed dementia.
17
 The detection of dementia was recorded in 47/88 of 
dementia patients. Eight of these patients had been found to have a false-positive diagnosis. 
Furthermore, delirium was recorded in only 31 out of 77 delirious patients, who were diagnosed by 
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the researchers.
17
 Furthermore, poor documentation and detection of underlying causes may result in 
under-or over- treatment
17
 as explicit identification of cognitive impairment such as delirium has been 
correlated with better outcomes in term of lower mortality and shorter in-patient hospital stays.
18
 
Missing ACB as the cause, especially during the short encounter with patients in primary care setting 
may affect patients‘ management in many sphere including patients‘ medications. Pharmacist spend at 
the least 60 minutes with patients during the HMR process, if pharmacists  can then include a 
validated cognition tests tools and calculate the ACB to include their results in the findings report, this 
may provide the treating doctor with valuable information and possible early intervention to improve 
patients quality of life. However, this hypothesis is yet to be tested in the parent study of this review, 
which the author is currently undertaking. 
1.1 Medications related issues 
Medication‐related cognitive impairments arising from poor medication management can result in 
significant morbidity and secondary care admissions.
19
 It has been demonstrated that medications 
contribute to about 40% of cases of delirium.
20
 Furthermore, medication errors and adverse drug 
events including those that are related to cognition may result in admission to intensive care units.
21
 
One study showed that 6.5% of all admissions to secondary care  units are caused by adverse drug 
reactions.
19
 Also, the study  found that each year 6000 deaths are associated with such events in 
England.
19
 Another study, which considered impaired cognition as the essential predictor of avoidable 
medication-related admissions to hospitals, showed that 5.6% of unplanned admissions were linked to 
medications and almost half (46.5%) of them were potentially avoidable.
22
 It has been shown that 
dementia people are often prescribed medications which impair and/or worsen their cognitions such as 
medications with sedative and/or anticholinergic activities.
23, 24
 Approximately 20-50% of dementia 
patients have been shown to take at least one medication with anticholinergic properties.
21
 Moreover, 
dementia patients may fail to identify potential medications errors as they less likely to appreciate 
adverse reaction, ask about their prescriptions or any change in their drugs and know whether they 
need monitoring.
25, 26
 Thus, a complete medication review should be considered to improve cognitive 
impairment care.
21
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2 Pharmacist role in early detection of cognitive impairment 
Pharmacists can play an active role in early recognition and prevention of medication-induced 
cognitive impairment when consider that the ACB is actually a medications adverse effects, i.e. their 
prevention is an integrated activity to the pharmacy profession. It has been shown that pharmacists 
were able to decrease the rate of preventable adverse drug reaction after discharge from hospital 
through patient counselling, telephone follow up and medication review.
27
 Additionally, collaboration 
between pharmacists and doctors to investigate treatment, patient management and pharmacotherapy 
has been used in different countries to improve prescribing and disseminate new guidelines and 
knowledge.
28
 One study (2001)
28
 with elderly subjects showed that the use of antidepressants with 
highly anticholinergic activities reduced and those with less anticholinergic properties increased 
through continuing medical education conducted by pharmacists and doctors.
28
 Moreover, it has been 
demonstrated that the educational program resulted in a significant reduction in the use of 
antipsychotic medication, which also exhibits anticholinergic properties, with no rise in the 
prevalence of behavioural problems.
29
 This may result in less anticholinergic burden including 
medication-induced cognitive impairment. Furthermore, He and Ball showed in their theoretical study 
that the reduction in anticholinergic burden (ACB) score by one can be achieved in 85% of the cases 
with score of 3 and 59% of the cases with score of 1 by altering the medication regimen based on 
appropriate practice guidelines.
30
 The Aging Brain Program at Indiana University also developed a 
guideline which is composed of a list of medications that can be used as alternatives to the 
medications with definite anticholinergic activities. The use of this guideline may help health 
professionals to provide care for individuals who suffer from cognitive impairment including 
delirium, mild cognitive impairment or dementia..
31
 Another study with elderly frail subjects showed 
that the anticholinergic drug scale (ADS) score reduced significantly after pharmacist-initiated 
medication changes.
32
 However, the same study found that medication changes did not reduce the 
dryness of the mouth or the serum anticholinergic activity (SAA) significantly.
32
 
Table 1 lists the commonly used assessment tools. As pharmacists do not undertake training in 
cognitive assessment as core skill in their undergraduate program, but their role as member of the 
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primary care team is within the pharmacist scope of practice, most assessment tools, but not K10 or 
WAYM, are not feasible to be used unless further training is completed post-graduation to be able to 
produce consistent interpretation of the results.   
3 Conclusion 
A substantial number of screening tests exist including MMSE, RUDAS, ADAS-Cog, PAS, KICA-
Cog, K10 and WAYM.  
One of the pharmacist core professional activities is to reduce medications adverse effects. ACB, 
when it is not the main indication of the medications prescribed to the patients is considered as side 
effects. Accordingly calculating the total score of the ACB caused by the patient medication 
theoretically can be used to guide reduction and management of medications to improve patients‘ 
quality of life. However, the same score may not produce the same effect in all patients, accordingly a 
supporting tool the early detect the effect of the score on the patient cognitive functioning is 
important. The pharmacist has this opportunity to spend 60 minutes with the patient during home 
medication review, it is hypothesis that if the pharmacist calculated the ACB total score and 
administered the K10 and WAYM and provide those results to the treating doctor as part of the HMR 
report, it may guide the doctor management of the patient medication or trigger a referral of the 
patient for further investigations leading to better health outcomes and quality of life. However further 
research is required to prove this hypothesis to be actual or null.  
4 Reference
8 
 
 
1. Jansen C, Miaskowski C, Dodd M, Dowling G, Kramer J. Potential mechanisms for 
chemotherapy-induced impairments in cognitive function. Oncol Nurs Forum 2005; 
32(6): 1151-63. 
2. Gyurak A, Goodkind MS, Madan A, Kramer JH, Miller BL, Levenson RW. Do tests of 
executive functioning predict ability to down-regulate emotions spontaneously and when 
instructed to suppress? Cogn Affect Behav Neurosci 2009; 9(2): 144-52. 
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive 
impairment: clinical characterization and outcome. Arch Neurol 1999; 56(3): 303-8. 
4. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, et al. Mild 
cognitive impairment – beyond controversies, towards a consensus: report of the 
International Working Group on Mild Cognitive Impairment. J Intern Med 2004; 256(3): 
240-6. 
5. Campbell NL, Boustani MA, Lane KA, Gao S, Hendrie H, Khan BA, et al. Use of 
anticholinergics and the risk of cognitive impairment in an African American population. 
Neurology 2010; 75(2): 152-9. 
6. Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. 
Anticholinergic medication use and cognitive impairment in the older population: the 
medical research council cognitive function and ageing study. J Am Geriatr Soc 2011; 
59(8): 1477-83.  
7. Gustafson Y, Brannstrom B, Norberg A, Bucht G, Winblad B. Underdiagnosis and poor 
documentation of acute confusional states in elderly hip fracture patients. J Am Geriatr 
Soc 1991; 39(8): 760-5. 
8. Francis JSS, Martin D, Kapoor W. Delirium in elderly general medical patients: common 
but often unrecognised. Clin Res 1988; 36(711A). 
9. vonAmmon Cavanaugh S. The prevalence of emotional and cognitive dysfunction in a 
general medical population: using the MMSE, GHQ, and BDI. Gen Hosp Psychiatry 
1983; 5(1): 15-24. 
10. Inouye SK. The dilemma of delirium: clinical and research controversies regarding 
diagnosis and evaluation of delirium in hospitalized elderly medical patients. Am J Med 
1994; 97(3): 278-88. 
11. Margolis RL. Nonpsychiatrist house staff frequently misdiagnose psychiatric disorders in 
general hospital inpatients. Psychosomatics 1994; 35(5): 485-91. 
12. Armstrong SC, Cozza KL, Watanabe KS. The misdiagnosis of delirium. Psychosomatics 
1997; 38(5): 433-9. 
13. Michel E, Rousseau F, Cole M, Primeau F, et al. Prevalence and detection of delirium in 
elderly emergency department patients. Can Med Assoc J 2000; 163(8): 977-81. 
14. Johnson JC, Kerse NM, Gottlieb G, Wanich C, Sullivan E, Chen K. Prospective versus 
retrospective methods of identifying patients with delirium. J Am Geriatr Soc 1992; 
40(4): 316-9. 
15. Inouye SK. Delirium in older persons. N Engl J Med 2006 ; 354(11): 1157-65. 
16. Bales JW, Wagner AK, Kline AE, Dixon CE. Persistent cognitive dysfunction after 
traumatic brain injury: A dopamine hypothesis. Neurosci Biobehav Rev 2009; 33(7): 
981-1003.  
9 
 
 
17. Laurila JV, Pitkala KH, Strandberg TE, Tilvis RS. Detection and documentation of 
dementia and delirium in acute geriatric wards. Gen Hosp Psychiatry 2004; 26(1): 31-5. 
18. Rockwood K, Cosway S, Stolee P, Kydd D, Carver D, Jarrett P, et al. Increasing the 
recognition of delirium in elderly patients. J Am Geriatr Soc 1994; 42(3): 252-6. 
19. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug 
reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 
2004 ; 329(7456): 15-9. 
20. Flacker JM, Marcantonio ER. Delirium in the elderly. Optimal management. Drugs 
Aging 1998; 13(2): 119-30. 
21. Maidment ID, Fox C, Boustani M, Katona C. Medication management—the missing link 
in dementia interventions. Int J Geriatr Psychiatry 2012; 27(5): 439-42. 
22. Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM. Frequency of and risk factors 
for preventable medication-related hospital admissions in the Netherlands. Arch Intern 
Med 2008; 168(17): 1890-6. 
23. Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum 
anticholinergic activity in a community-based sample of older adults: relationship with 
cognitive performance. Arch Gen Psychiatry 2003; 60(2): 198-203. 
24. Starr JM, Whalley LJ. Drug-induced dementia. Incidence, management and prevention. 
Drug Saf 1994; 11(5): 310-7. 
25. Maidment ID, Lelliott P, Paton C. Medication errors in mental healthcare: a systematic 
review. Qual Saf Health Care 2006; 15(6): 409-13. 
26. Barber ND, Alldred DP, Raynor DK, Dickinson R, Garfield S, Jesson B, et al. Care 
homes' use of medicines study: prevalence, causes and potential harm of medication 
errors in care homes for older people. Qual Saf Health Care 2009; 18(5): 341-6. 
27. Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E, et al. Role 
of pharmacist counseling in preventing adverse drug events after hospitalization. Arch 
Intern Med 2006; 166(5): 565-71. 
28. Eijk MECv, Avorn J, Porsius AJ, Boer Ad. Reducing prescribing of highly 
anticholinergic antidepressants for elderly people: randomised trial of group versus 
individual academic detailing. BMJ 2001; 322(7287): 654. 
29. Ray Wa TJAMKG, et al. Reducing antipsychotic drug use in nursing homes: A 
controlled trial of provider education. Arch Intern Med 1993; 53(6): 713-21. 
30. He Z, Ball PA. Can medication management review reduce anticholinergic burden 
(ACB) in the elderly? Encouraging results from a theoretical model. Int Psychogeriatr 
2013; 25(09): 1425-31. 
31. Anticholinergic Cognitive Burden Scale: Aging Brain Program of the Indiana University 
Center for Aging Research; 2012. [cited 2016 3rd February]. Available from: 
http://www.agingbraincare.org/uploads/products/ACB_scale_-_legal_size.pdf. 
32. Kersten H, Molden E, Tolo IK, Skovlund E, Engedal K, Wyller TB. Cognitive effects of 
reducing anticholinergic drug burden in a frail elderly population: a randomized 
controlled trial. J Gerontol A Biol Sci Med Sci 2013; 68(3): 271-8. 
33. Tombaugh TN, McIntyre NJ. The mini-mental state examination: a comprehensive 
review. J Am Geriatr Soc 1992; 40(9): 922-35. 
10 
 
 
34. Shigemori K, Ohgi S, Okuyama E, Shimura T, Schneider E. The factorial structure of the 
Mini-Mental State Examination (MMSE) in Japanese dementia patients. BMC Geriatr 
2010; 10: 36. 
35. Storey JE, Rowland JTJ, Conforti DA, Dickson HG. The Rowland Universal Dementia 
Assessment Scale (RUDAS): a multicultural cognitive assessment scale. Int 
Psychogeriatr 2004; 16(01): 13-31. 
36. Chu LW, Chiu KC, Hui SL, Yu GK, Tsui WJ, Lee PW. The reliability and validity of the 
Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the 
elderly Chinese in Hong Kong. Ann Acad Med Singapore 2000; 29(4): 474-85. 
37. Kolibas E, Korinkova V, Novotny V, Vajdickova K, Hunakova D. ADAS-cog 
(Alzheimer's Disease Assessment Scale-cognitive subscale)--validation of the Slovak 
version. Bratisl Lek Listy 2000; 101(11): 598-602. 
38. Jorm AF, Mackinnon AJ, Christensen H, Henderson AS, Jacomb PA, Korten AE. The 
psychogeriatric assessment scales (PAS): further data on psychometric properties and 
validity from a longitudinal study of the elderly. Int J Geriatr Psychiatry 1997; 12(1): 93-
100. 
39. Jorm AF, Mackinnon AJ, Henderson AS, Scott R, Christensen H, Korten AE, et al. The 
Psychogeriatric Assessment Scales: a multi-dimensional alternative to categorical 
diagnoses of dementia and depression in the elderly. Psychol Med 1995; 25(3): 447-60. 
40. LoGiudice D, Smith K, Thomas J, Lautenschlager NT, Almeida OP, Atkinson D, et al. 
Kimberley Indigenous Cognitive Assessment tool (KICA): development of a cognitive 
assessment tool for older indigenous Australians. Int Psychogeriatr 2006; 18(2): 269-80. 
41. A Guide to the K10 Symptom Scale 2005 [cited 2016 15th January]. Available from: 
www.mhima.org.au/_literature_73655/K10. 
42. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, et al. Short 
screening scales to monitor population prevalences and trends in non-specific 
psychological distress. Psychol Med 2002; 32(6): 959-76. 
43. Andrews G, Slade T. Interpreting scores on the Kessler Psychological Distress Scale 
(K10). Aust N Z J Public Health 2001; 25(6): 494-7. 
44. Worried about your memory? 2013 [cited 2015 14th December]. Available from: 
https://fightdementia.org.au/sites/default/files/2013_WAYM-DL_6pp.pdf. 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
Table 1 - Summary of common assessment tools used for clinical diagnosis of Cognitive 
Function 
 
Tool  comments 
MMSE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MMSE is a screening tool that provides a brief, objective measure of cognitive function.33, 34  
MMSE scores are useful in documenting cognitive change serially and in estimating the severity of 
cognitive impairment quantitatively. 33, 34 Despite the wide range of cognitive screening tests 
available, MMSE is the most widely used and popular clinical measure due to its availability in 
many languages.33 The MMSE is used widely in studies and community surveys.33 It forms part of 
the diagnostic interview schedule and a structured interview used recently in a large five-site 
epidemiological catchment area study promoted by the National Institute of Mental Health.33, 34 
Additionally, MMSE has been incorporated into several standardised interviews designed to help 
diagnose dementia and to assess cognitive impairment.33, 34 The National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s disease and Related Disorders 
Association has recommended MMSE  as one of the tests  to document the clinical diagnosis of 
possible Alzheimer’s disease.33  The MMSE has a maximum score of 30 points and consists of a 
range of questions which can be administered ordinarily in 5-10 minutes.33, 34 The questions are 
categorised into seven groups, each representing a different cognitive function domain. They are 
orientation to time (5 points), orientation to place (5 points), attention and calculation (5 points), 
registration of three words (3 points), recall of three words (3 points), language (8 points) and 
visual construction (1 point).33 Although MMSE has been shown to fulfil its original goal of 
providing a brief screening test that quantitatively assesses the severity of cognitive impairment 
and documents cognitive changes occurring over time, it should not, by itself, be used as a 
diagnostic tool to identify dementia.33  
RUDAS 
 
RUDAS is a multicultural cognitive assessment scale.35 It is short cognitive screening instrument 
designed to minimise the effects of cultural learning and language diversity on the assessment of 
baseline cognitive performance.35 When administering the RUDAS, it is important that the 
respondent is encouraged to communicate in the language with which they are most competent 
and comfortable.35 Also, the test taker should be  as relaxed as possible, because test anxiety can 
interfere with performance on cognitive tests35. Additionally, the RUDAS test is conducted in a 
quiet area, so the test taker can hear clearly.35 It is significant to identify at the start of the 
assessment, if the test taker has  hearing problems and accommodate for this as much as possible 
such as  speaking slowly and clearly and encouraging test takers to wear any hearing aids 
necessary.35 Furthermore, RUDAS provides a large print version of the test if the test taker suffers 
severe hearing impairment.35 RUDAS also ensures that the test taker is using reading glasses when 
necessary and that there is sufficient light in the room.35 At the end of the RUDAS test, the scores 
will be added up for each item to obtain a total score out of 30.35 Test takers with scores of 22 or 
less will be concluded to possibly have cognitive impairment, and will be referred on for further 
investigation by the relevant physician.35 If  test takers suffer a physical disability (e.g. vision, 
hearing, hemiparesis, amputee, stroke, aphasia) which may affect their ability to perform certain 
items on the RUDAS, it is important to  interpret any total score less than 22 with caution.35 Thus, 
further research is necessary to assess validity of the RUDAS in this sub-group of patients.35 
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ADAS-
Cog 
It has been reported that ADAS-cog is the most popular cognitive testing instrument used in 
clinical trials and a sensitive cognitive function assessment scale for Alzheimer's Disease (AD).36 Its 
validity and reliability have been established in the original English version.36 ADAS-cog consists of 
eleven items which are designed to measure the severity of the most important and the core 
symptoms of (AD) including orientation, memory, praxis function and language disturbances.37 
ADAS-cog is not designed for use as a diagnostic tool, but scores on the scale discriminate patients 
with clinically diagnosed AD from non-dementia subjects.36 Its sensitivity to detect change has 
been documented by longitudinal follow-up data.36 On average, AD patients show an increase in 
ADAS-cog scores of about 7 to 8 points per year interval.36 It has been reported that ADAS-cog is 
more sensitive than other dementia rating scales like Folstein MMSE.36 Thus, ADAS-cog is 
commonly employed as a primary outcome measure to assess the effects of cognitive enhancing 
drugs in clinical trials of new drug treatment for AD.36  
PAS The PAS is designed to gather information on the main psychogeriatric disorders: depression and 
dementia.38, 39 PAS differs from conventional approaches to psychogeriatric assessment in a 
number of significant ways.38 Psychogeriatric assessment is generally the province of people with 
extensive specialist training in geriatrics or psychiatry.38 PAS aims to assist a wider range of people 
to carry out psychogeriatric assessment, so it provides a straightforward method of gathering and 
interpreting the relevant information without the necessity for prolonged training. 38, 39 
Furthermore, in conventional thinking, people having depression or dementia are in a distinct 
group from ‘normal’ people.38 It is true that when people with psychogeriatric disorders are seen 
by health care workers they appear to be categorically apparent from other people.38 However, 
when the whole elderly population is looked at, depression and dementia are seen as part of a 
continuum.38, 39 For instance, there is a continuum ranging from successful cognitive ageing at one 
end to severe dementia at the other.38 There is a different continuum ranging from positive well-
being in old age to severe depression.38 However, the PAS aims to put people along a number of 
appropriate continua and helps by collecting information in a systematic way.38 The PAS also gives 
guidance on how this information should be interpreted by comparing the results to the normal 
range found in the society.38 Thus, PAS assesses psychogeriatric disorders on scales rather than as 
categories. Given that PAS provides a method of assessing psychogeriatric disorders, it does not 
tell the user what action to take if problems are found, so the use of the information in PAS is only 
to guide care decisions which should be based on the user’s professional expertise.38, 39 
KICA-
Cog 
The KICA was developed in response to the need for a validated cognitive screening tool for older 
Indigenous Australians living in rural and remote areas.40 The KICA-Cog section is validated with 
Indigenous Australians aged 45 years and above from the Kimberley and Northern Territory.40 The 
KICA–cog has a maximum score of 39. A score of 33/39 and below indicates possible dementia.40 
Those with a low KICA-Cog score should be referred to a doctor for medical screens to rule out 
other causes of cognitive impairment, some of which are reversible, or to confirm dementia.40 
KICA-Cog’s cognitive assessment contains the informant (carer) report.  which has been validated 
with a score of 3/16 or above indicating that further investigations are required.40 Other sections 
of the KICA tool are for information gathering to assist in determining subtypes, severity, 
differential diagnoses and management.40 As language skills are assessed in the cognitive section it 
is recommended that an interpreter be used when required.40 Furthermore, KICA-cog contains a 
visual naming task.40 If an individual is unable to name a certain photo (crocodile or emu) because 
of their own cultural reasons it can be replaced by the dog or horse pictures.40 Thus,  KICA-Cog 
appears to be a reliable assessment tool in an Australian older ordinarily living indigenous 
population for cognitive impairment.40 
K10 The K10 is a simple widely recommended tool to measure of psychological distress as well as the 
outcomes after different mental health problems as the K10 is available to the public through the 
website of Clinical Research Unit for Anxiety and Depression to identify who requires treatment as 
anyone can administer it.
41, 42
 There are five responses in the ten item scale. Score one being none 
of the time and five all of the time. Thus, total scores ranges from 10 which means no distress to 50 
which means sever distress.
42
 Composite International Diagnostic Interview (CIDI) identifies 
people with a score falls in between 0-15 to have the risk of one quarter of the population of 
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meeting the depressive or anxiety disorder criteria.
41, 43
 People with a score falls in between 16-30 
have 25% chance of developing a current depressive or anxiety disorder and chance of 1% of ever 
attempting a suicide in their life.
41, 43
  People with a score falls in between 30-50 have 75% chance 
of meeting the criteria for a depressive or anxiety disorder and a chance of 6% of ever attempting a 
suicide in their lives.
41
  
WAYM The Worried about your memory (WAYM) is a tool developed by Alzheimer‘s Australia and aims 
to increase awareness of the early symptoms and signs of dementia. WAYM encourages people to 
seek help if they have memory concerns.
44
 WAYM contains 12 statements which the person should 
comments on them by choosing either rarely, sometimes or often. If a person has ticked 
‗sometimes‘ or ‗often‘ it is recommended that he /she see his/her doctor.
44
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Table 2 – Literature Selection by contribution to Research Concept 
 
Primary author 
& reference 
[ n(total) = 44] 
Impact Citations Contribution to the research concept 
Gyurak A. (2) 3.287 80 Definition of cognitive impairment. . 
Gustafson Y. (7) 4.572 218 Cognitive impairment is misdiagnosed by health care 
professionals.  
vonAmmon 
Cavanaugh S. (9) 
2.606 202 Cognitive function is rarely formally assessed.  
Inouye SK.(10) 5.003 611 Problem associated with cognitive impairment 
 
Michel E. (13) 5.959 269 Diagnosis of delirium by ED  
Inouye SK. (15) 55.873 1418 Mild dementia and delirium.  
Laurila JV. (17) 2.606 97 different cognitive impairments misdiagnosed in 
hospital.   
Maidment ID. 
(21) 
2.419 2 Medication errors and adverse drug events related to 
cognition and hospital admission.  
Mulsant BH. (23) 14.48 249 Medications prescribing for demented people. 
He Z. (30) 1.934 9 Possibility of reducing ACB by medications regimen 
changes.  
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Table 3 – Search example using Medline data base 
 
Search terms  First search: abstracts  Second filter: English 
language, Journal, 
elderly (65+years old)  
Third filter: Full 
text papers 
Cognitive impairment 45,920 17,135 4,927 
Cognitive impairment 
AND diagnosis 
15,305 7,702 
 
2,155 
Cognitive scales  4,383 1,772 561 
Dementia  95,025 40,169 10,498 
Delirium  12,850 3,656 949 
Pharmacist role  2,641 301 94 
Mini-mental state 
examination (MMSE) 
4,786 3,315 1,084 
the Rowland dementia 
assessment scale 
(RUDAS) 
19 14 6 
the Alzheimer‘s Disease 
Assessment Scale- 
Cognition (ADAS-Cog) 
49 36 12 
Barriers and problems 
cognitive impairment 
diagnosis 
15,816 3,089 1,149 
Cognitive impairment 
Cognitive impairment 
AND diagnosis 
Cognitive Scales 
Dementia Delirium 
Pharmacist role 
6,676 2,519 665 
 
 
  
